Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

811 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidziński M, Kim JW, Nam JH, Madry R, Hernández C, Mora PAR, Ryu SY, Milenkova T, Lowe ES, Barker L, Scambia G. Penson RT, et al. Among authors: barker l. J Clin Oncol. 2020 Apr 10;38(11):1164-1174. doi: 10.1200/JCO.19.02745. Epub 2020 Feb 19. J Clin Oncol. 2020. PMID: 32073956 Free PMC article. Clinical Trial.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Saad F, et al. Among authors: barker l. Lancet Oncol. 2023 Oct;24(10):1094-1108. doi: 10.1016/S1470-2045(23)00382-0. Epub 2023 Sep 12. Lancet Oncol. 2023. PMID: 37714168 Clinical Trial.
Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial.
Armstrong AJ, Clarke N, Oya M, Procopio G, de Menezes J, Guedes JD, Ghatalia P, Nolè F, Din O, Spiegelhalder P, Mincik I, van Alphen R, Lumen N, Hosius C, Zhou D, Barker L, Dujka M, Saad F. Armstrong AJ, et al. Among authors: barker l. Eur Urol Oncol. 2023 Oct 27:S2588-9311(23)00218-3. doi: 10.1016/j.euo.2023.10.004. Online ahead of print. Eur Urol Oncol. 2023. PMID: 39492050 Free article.
IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer.
Palmieri C, Szydlo R, Miller M, Barker L, Patel NH, Sasano H, Barwick T, Tam H, Hadjiminas D, Lee J, Shaaban A, Nicholas H, Coombes RC, Kenny LM. Palmieri C, et al. Among authors: barker l. Breast Cancer Res Treat. 2017 Nov;166(2):527-539. doi: 10.1007/s10549-017-4427-x. Epub 2017 Aug 9. Breast Cancer Res Treat. 2017. PMID: 28795252 Free PMC article. Clinical Trial.
Impacts of the COVID-19 pandemic on access to sexual and reproductive health services for women and transgender people with disabilities in Canada: a qualitative study.
Evans M, Rego A, Ogbonna N, Welsh K, Zafar SK, Barker LC, Berndl A, Mont JD, Lunsky Y, McPherson A, Tarasoff LA, Vandermorris A, Brown HK. Evans M, et al. Among authors: barker lc. Sex Reprod Health Matters. 2024 Dec 13:1-23. doi: 10.1080/26410397.2024.2441027. Online ahead of print. Sex Reprod Health Matters. 2024. PMID: 39668741 Free article.
811 results